EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.
复制标题
DOI:
10.1021/acsmedchemlett.5b00037
复制
发表时间:
2015-05-14
影响因子:
4.2
通讯作者:
Copeland, Robert A.
中科院分区:
文献类型:
--
作者:
Campbell, John E.;Kuntz, Kevin W.;Knutson, Sarah K.;Warholic, Natalie M.;Keilhack, Heike;Wigle, Tim J.;Raimondi, Alejandra;Klaus, Christine R.;Rioux, Nathalie;Yokoi, Akira;Kawano, Satoshi;Minoshima, Yukinori;Choi, Hyeong-Wook;Scott, Margaret Porter;Waters, Nigel J.;Smith, Jesse J.;Chesworth, Richard;Moyer, Mikel P.;Copeland, Robert A.
Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pathobiology has been hampered by the lack of in vivo-active tool compounds for this enzyme. Here we report the discovery and characterization of EPZ011989, a potent, selective, orally bioavailable inhibitor of EZH2 with useful pharmacokinetic properties. EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft model of human B cell lymphoma. Hence, this compound represents a powerful tool for the expanded exploration of EZH2 activity in biology.
登录
查看更多内容
影响因子:
82.9
作者:
通讯作者:
--
影响因子:
4.2
作者:
Nasveschuk, Christopher G.;Gagnon, Alexandre;Harmange, Jean-Christophe P.
通讯作者:
Harmange, Jean-Christophe P.
影响因子:
56.9
作者:
Cao, R;Wang, LJ;Zhang, Y
通讯作者:
Zhang, Y
影响因子:
10.5
作者:
Kuzmichev, A;Nishioka, K;Reinberg, D
通讯作者:
Reinberg, D
DOI:
10.1073/pnas.1012525107
发表时间:
2010-12-07
影响因子:
11.1
作者:
Sneeringer, Christopher J.;Scott, Margaret Porter;Copeland, Robert A.
通讯作者:
Copeland, Robert A.